Clinical Trial Update: Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating bendamustine, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bendamustine (Bendamustine)
• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)

Snippet

Sponsor: Austrian Forum Against Cancer | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED